Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRI

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 29, 2018

Primary Completion Date

December 13, 2021

Study Completion Date

February 8, 2024

Conditions
Normal Physiology
Interventions
DRUG

Methylphenidate Pill

Oral methylphenidate (60 mg) given 30 minutes prior to bolus \[11C\]raclopride

DRUG

Oral Placebo

Oral PL will be given 30 minutes prior to bolus \[11C\]raclopride injection

DRUG

Intravenous Placebo

Intravenous Placebo given 30 minutes post bolus injection of \[11C\]raclopride.

DRUG

Intravenous methylphenidate

Intravenous methylphenidate 0.25 mg/kg in 3ml sterile saline given 30 minutes post bolus injection of \[11C\]raclopride.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

NCT03326245 - Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRI | Biotech Hunter | Biotech Hunter